Hematopathology
March 2014, Vol. 1, No. 1
Instruction to Authors
Hematopathology is the official journal of San Diego Society of Hematopathology and is dedicated to publication
of original works related to the study of hematopathology. Hematopathology welcomes submission of clinical,
translational, and experimental research papers, and also publish editorials, review articles, case reports, letters to
the editors and meeting proceedings. In addition, Hematopathology encourages submissions with an
emphasis on the needs of practicing pathologists in the community.
GENERAL POLICY
Hematopathology is an open-access online journal and publishes accepted papers online. Hematopathology
considers all manuscripts on the strict condition that they are the property (copyright) of the submitting
author(s), have been submitted only to Hematopathology, that they have not been published elsewhere
(except in the form of an abstract, or as part of a published lecture or thesis) and are not currently under
consideration for publication by another journal.
It is the responsibility of the corresponding author to ensure that all authors have contributed to, read and
approved the final manuscript for submission. The authors should keep a copy of manuscript submitted in case
of revision, rejection, loss or damage. Receipt of manuscript will be acknowledged and a decision regarding
acceptance made as soon as possible. Accepted manuscripts may be subject to editorial revision without
notice. The authors will have one opportunity to proof-read the manuscript before publication.
With submission to Hematopathology, authors are considered to the agreement for the transfer of
copyright to the publisher, San Diego Society of Hematopathology. All accepted manuscripts, artwork,
and photographs become the property of the publisher.
Authors are themselves responsible for obtaining permission to reproduce copyright material from other
sources. http://comms.informahealthcare.com/
Review Policy
Currently, each submission will be reviewed at least by two editors assigned by the Editor-in-Chief, who
will make the final decision. The editors will do their best to ensure rapid review turn-around and quick
publication. Hematopathology considers all manuscripts at the Editors' discretion; the Editors' decision is
final.
Disclaimer
While the advice and information in the article are believed to be true and accurate on the date of its
going to press, neither the authors nor the editors can accept any legal responsibilities for any errors or
omissions that may be made. The publication makes no warranty, expressed or implied, with respect to
the materials contained within.
PREPARATION OF MANUSCRIPT
All manuscripts should be written in standard grammatical English using computer software, arranged in
the following order and saved as a single DOC (Word) file including all components of the manuscript:
1.
2.
3.
4.
5.
cover letter
title page
abstract and keywords
main text
acknowledgements, if any
Hematopathology
6.
7.
8.
9.
March 2014, Vol. 1, No. 1
references
tables, if any
figure legends, if any
figures, if any
Cover Letter
The cover letter should include name, degree, address, telephone, fax and email of the corresponding
author. A statement that all authors have contributed to, read and approved the final manuscript for
submission should be included if there are multiple authors. Any editorial or financial conflict of interest
(e.g., consultancy, stock ownership, equity interests, patent or licensing agreements) should be clearly
disclosed in the cover letter. The disclosure statement must be submitted upon acceptance.
Abstract and Keywords
The abstract should not exceed 250 words that concisely summarize the study’s purpose, significant
findings and conclusions. Include up to 6 keywords or phrases at the end of the abstract. Each
keyword should be separated by a comma.
Main Text
The main text should be double-spaced and include Introduction, Materials and Methods (optional),
Results and Discussion. The Introduction should be succinct, clearly stating the purpose and rationale
of the study. In Materials and Methods, the procedures should be described in sufficient detail to allow
duplication by an independent observer. Results and Discussion may be combined or divided. They
should be written concisely and logically with emphasis on novel findings.
Acknowledgements
All acknowledgements (if any) should be included at the end of the main text before references and
may include grant and administrative support.
References
Reference published in Hematopathology should begin on a new page, be single-spaced and numbered
in order of citation in the text, including citations in tables and figure legends. References should follow
the Council of Science Editors (CSE) Citation & Sequence format.
Only works actually cited in the text should be included in the references.
Citations should be Arabic numbers inside parenthesis, such as (1).
If there are 1 to 6 authors, list all authors. If there are more than 6 authors, list the first 3 authors
followed by et al.
Formatting examples:
Journal article: 1. Mann S, Graham MA, Bregman DB, Ivy P, Chaney SG. Oxaliplatin: a review of
evolving concepts. Cancer Investigation 2002; 20: 246-263.
Journal article with more than 6 authors: 2. Bishop JF, Matthews JP, Young GAR, et al. A randomized
trial of high dose cytarabine in induction in acute myeloid leukemia. Blood 1996; 87: 1710-1717.
Book Chapter: 3. Sallan SE, W einstein HJ. Childhood acute leukemia. In: Nathan DG, Oski FA, editors.
Hematology of Infancy and Childhood. Vol 2. Philadelphia, PA: Saunders; 1987. p 1028-1039.
Conference proceedings: 4. Polliack A, Seymour J, Van Besien K, editors. Proceedings from the
Sixth International Workshop on Non-Hodgkin Lymphoma; 2007 Nov 16-17; Boston. New York:
Informa Healthcare; 2008. 73 p.
Hematopathology
March 2014, Vol. 1, No. 1
Dissertations or Thesis: 5. Smithers AJ. A comparative study of diet and cancer, types of cancer,
effective cancer-fighting foods and nutrients and research [dissertation]. Philadelphia (PA): University of
Pennsylvania; 1997. 156 p. Available from: University Microfilms, Ann Arbor MI; AAG9103322.
Webpage: 6. British Medical Journal [Internet]. Stanford, CA: Stanford Univ; 2004 July 10 - [cited 2004
Aug 12]; Available from: http://bmj.bmjjournals.com/
Internet databases: 7. Prevention News Update Database [Internet]. Rockville (MD): Centers for Disease
Control and Prevention (US), National Prevention Information Network. 1988 Jun - [cited 2001 Apr 12].
Available from: http://www.cdcnpin.org/
When referencing a paper presented at a meeting with a published abstract, reference the
published abstract. Always give an abstract number: 8. Mueller MC, Gattermann N, Lahaye T, et al.
Dynamics of BCR-ABL mRNA transcript expression in newly diagnosed chronic myeloid leukemia
patients treated with imatinib or interferon alpha [abstract]. Blood. 2002; 100: (Supplement). Abstract
1413.
When referencing a paper presented at a meeting but not published in any form, include the title,
the meeting name, the date of presentation, and the geographic location: 9. Sholer A. Emerging
technologies in treatment of pediatric leukemia. Paper presented at Annual Meeting of the Association
of American Medical Colleges. October 14, 1998. Washington, DC.
Further examples and information can be found in The CSE Manual for Authors, Editors, and Publishers,
Seventh Edition. Periodical abbreviations should follow the style given by Index Medicus.
Tables
All tables should be cited consecutively in the main text by Arabic numbers (Table 1, Table 2, etc).
Type each table with a descriptive title on a separate page after the references. Provide explanations
for any nonstandard abbreviations in footnotes to the table.
Figure Legends
Figure legends including figure number, a short title and detailed description should be embedded at
the end of text file.
Figures
All figures should be cited consecutively in the main text by Arabic numbers (Figure 1, Figure 2, etc).
All figures must be prepared at 600 dpi resolution and embedded in the Word File at the end of the
manuscript. If the single Word File is too large to be submitted by e-mail, then figures can be
submitted in either TIFF or JPEG format as separate files labeled with the corresponding numbers. If
figures have to be submitted separately from the main Word file, a PDF file that includes all
components of the manuscript including figures has to be submitted at the same time. Photographs of
a person should render them unidentifiable or include their written permission.
EDITORIAL POLICIES
All submissions should be emailed to San Diego Society of Hematopathology at:
sdsh@sdhematopathology.org .
Ethics and Consent
Hematopathology
March 2014, Vol. 1, No. 1
Do not use patients' names, initials, or hospital numbers, especially in illustrative material. Identifying
information should not be published in written descriptions, photographs, and pedigrees unless the
information is essential for scientific purposes and the patient (or parent or guardian) gives written
informed consent for publication. Informed consent for this purpose requires that the patient be shown
the manuscript to be published.
Papers including animal experiments or clinical trials must be conducted with approval by the local
animal care or human subject committees, respectively. As outlined by both COPE and ICMJE, all
clinical trials should be conducted according to the Declaration of Helsinki. All manuscripts, except
reviews, must include a statement in the abstract and the Methods section that the study was
approved by an Investigational Review Board (and/or Animal Care and Use Committee).
Publication Fee
Currently, there is no publication fee to publish on Hematopathology.
Contacts
All communications to Hematopathology should be addressed to:
Xiangdong (Don) Xu, MD, PhD,
Executive Editor, Hematopathology
3350 La Jolla Village Drive, MC113
San Diego, CA 92161
Phone: 858-642-1415
Email: xxu@ucsd.edu